

Index

- 5HT (5-hydroxytryptamine)
 synthesis, 142
 termination of action, 142–143
See also serotonin.
- 5HT1A receptor partial agonists
 atypical antipsychotics, 156–159
 vilazodone, 300–302
- 5HT1B/D receptors
 effects of atypical antipsychotics,
 159–160
 terminal autoreceptors, 159–160
- 5HT2A receptor antagonists, 318
 atypical antipsychotic actions,
 142–156
 effects on dopamine D2 receptors,
 151–156
 effects on extrapyramidal
 symptoms, 150
 effects on prolactin levels,
 150–151
 stimulating downstream dopamine
 release, 142–150
- 5HT2A receptors
 blocking downstream dopamine
 release, 142–150
- 5HT2C receptor antagonists, 313–318
 fluoxetine, 297
- 5HT2C receptors
 effects of atypical antipsychotics,
 159–162
 role in obesity treatment, 159
- 5HT3 receptor antagonists, 318–322,
 500, 559
- 5HT3 receptors
 effects of atypical antipsychotics,
 162
- 5HT6 receptor antagonists, 500
- 5HT6 receptors
 effects of atypical antipsychotics,
 162
- 5HT7 receptors
 effects of atypical antipsychotics,
 162–165
- Abeta peptides
 role in Alzheimer's disease, 505,
 507, 509
- ABT560, 500
- acamprosate, 385, 417, 556–558
- acetaminophen, 340
- acetylation of histones, 24
- acetylcholine, 5
 as brain's own nicotine, 543
 basis for cholinesterase treatment
 of dementia, 522–528
 cholinergic pathways, 524
 cholinergic receptors, 523–528
 precursors, 524
- acetylcholine transporters, 523
- acetylcholine vesicular transporter, 29
- acetylcholinesterase, 46, 522–525
- Adapin, 342
- adenosine antagonist
 caffeine, 469
- adiponectin, 565
- adolescents
 bipolar disorder, 386
 mania, 386
 mood stabilizer selection, 386
- affective disorders. *See* mood disorders.
- aggression
 disorders associated with, 85
 impulsive–compulsive behavior in
 psychiatric disorders, 574
 in schizophrenia, 84
- agomelatine, 159, 313–317, 457
- agonist action
 G-protein-linked receptors, 35–36
 ligand-gated ion channels, 56
- agonist spectrum
 G-protein-linked receptors, 35–43
 ligand-gated ion channels, 56–64
- agoraphobia
 in children, 386
- agouti-related peptide, 565
- agouti-related protein, 565
- akathisia, 95, 168
- Akiskal, Hagop, 243
- AKT (kinase enzyme)
 in schizophrenia, 128
- alcohol dependence, 551–559
- alcoholism treatment, 468
- allodynia, 425
- allosteric modulation
 ligand-gated ion channels, 65–67
- almorexant (SB649868), 463
- alolia
 in schizophrenia, 82
- alpha 1 adrenergic antagonists
 atypical antipsychotics, 173
- alpha 2 antagonists, 317–322
- alpha 2 delta ligands
 as anxiolytics, 403–405
- alpha 2A adrenergic agonists
 ADHD treatment, 495–499
- alpha-melanocyte stimulating
 hormone (alpha-MSH), 565
- alprazolam, 5, 49
- Alzheimer's dementia, 504
 and psychosis, 79
- Alzheimer's disease
 acetylcholine as target for current
 symptomatic treatment, 522–527
 aggressive and hostile symptoms, 85
 amyloid as target of disease-
 modifying treatment, 520–523
 amyloid cascade hypothesis,
 505–509
 basis for cholinesterase treatments,
 522–528
 beta amyloid plaques, 505–509
 beta secretase inhibitors, 522
 biomarker-enhanced early
 detection, 521
 biomarkers, 516–518
 causes, 503–505
 cholinergic deficiency hypothesis
 of amnesia in, 525
 cholinesterase inhibitors, 525–527
 clinical features, 503–505
 cognitive symptoms, 85
 diagnosis, 503–505
 diagnostic categories for
 Alzheimer's dementia, 519–520
 donepezil, 529
 galantamine, 527
 gamma secretase inhibitors,
 521–522
 genetic studies, 509
 glutamate hypothesis of cognitive
 deficiency, 527–534
 immunotherapy research, 521
 memantine, 527–531
 neurofibrillary tangles, 505–509
 neuroimaging biomarkers, 517–518
 pathology, 503–505
 positive symptoms, 85

Index

- Alzheimer's disease (cont.)
 possible Alzheimer's dementia category, 519–520
 possible benefits of lithium, 372
 probable Alzheimer's dementia category, 519–520
 prodromal stage, 515–519
 range of proposed targets, 533–536
 risk factors for disease progression, 515
 risk related to Apo-E, 509–510
 rivastigmine, 526–527
 role of Abeta peptides, 505, 507, 509
 role of amyloid precursor protein (APP), 505–507, 509
 role of pathological tau, 508
 search for a vaccine, 521
 targeting glutamate, 527–531
 testing of potential treatments, 533–536
 treatments for psychiatric and behavioral symptoms, 531–533
- Alzheimer's disease stages, 510–511
 amyloidosis with neurodegeneration and cognitive decline, 519–520
 amyloidosis with some neurodegeneration, 515–519
 asymptomatic amyloidosis, 511–515
 dementia stage, 519–520
 distinction of MCI from normal aging, 515–519
 first stage (preclinical), 511–515
 mild cognitive impairment (MCI), 515–519
 presymptomatic stage, 511–515
 second stage, 515–519
 symptomatic predementia stage, 515–519
 third (final) stage, 519–520
- amenorrhea, 95
 amisulpride, 168
 pharmacologic properties, 212
 amitifidine (triple reuptake inhibitor), 365
 amitriptyline, 6, 342
 amoxapine, 162, 342
 AMPA PAMs, 228
 AMPA receptor modulators, 228
 AMPA receptors, 101–102
 AMPAkinases, 228, 500
 amphetamine, 34, 327, 547
 ADHD treatment, 490–491
 brain's own (dopamine), 543
 wake-promoting agent, 468
- amygdala, 122
 fear response, 392–395
 neurobiology of fear, 392–395
 neuroimaging in schizophrenia, 122–126
 role in fear conditioning, 409–411
- amyloid precursor protein (APP)
 role in Alzheimer's disease, 505–507, 509
- amyotrophic lateral sclerosis (ALS), 379
- Anafranil, 342
- analgesics
 interactions with MAOIs, 340
- anandamide, 5, 543, 561
- anatomical basis of neurotransmission, 1–2
- anatomically addressed nervous system, 1–2
- anesthetics
 interactions with MAOIs, 335
- “angel dust”. *See* phencyclidine (PCP)
- anhedonia
 in schizophrenia, 82
- anorexia nervosa, 564
- antagonist action
 G-protein-linked receptors, 36–37
 ligand-gated ion channels, 57–59
- anticholinergics, 523
- anticonvulsants, 73
 as mood stabilizers, 373–380
- antidepressant action, 47
 atypical antipsychotics, 169–172
 comparison with placebo in clinical trials, 285
 debate over efficacy, 285–287
 definition of a treatment response, 285
 discovery of, 6
 disease progression in major depression, 289
 effects throughout the life cycle, 289
 efficacy in clinical trials, 285–287
 failure to achieve remission, 287
 general principles, 285–289
 goal of sustained remission, 285
 importance of achieving remission, 289
 in “real world” trials, 289
 STAR-D trial of antidepressants, 287
- antidepressant augmenting agents, 346–353
 brain stimulation techniques, 350–352
 buspirone, 301–302
 deep brain stimulation (DBS), 351–352
 electroconvulsive therapy (ECT), 350
 L-methylfolate, 346–350
 psychotherapy as an epigenetic “drug”, 352–353
 SAME (S-adenosyl-methionine), 350
 thyroid hormones, 350
 transcranial magnetic stimulation (TMS), 350–351
- antidepressant classes
 5HT_{2C} antagonism, 313–317
 alpha 2 antagonists, 317–322
 circadian rhythm resynchronizer, 313–317
 melatonergic action, 313–317
 monoamine oxidase inhibitors (MAOIs), 326–342
 monoamine transporter blockers, 289–346
 norepinephrine–dopamine reuptake inhibitors (NDRIs), 309–312
 selective norepinephrine reuptake inhibitors (NRIs), 312–313
 serotonin antagonist/reuptake inhibitors (SARIs), 322–326
 serotonin–norepinephrine reuptake inhibitors (SNRIs), 302–309
 serotonin partial agonist-reuptake inhibitors (SPARIs), 300–302
 serotonin selective reuptake inhibitors (SSRIs), 290–300
 tricyclic antidepressants, 312, 342–346
- antidepressant-induced bipolar disorder, 382
- antidepressant-induced mood disorders, 247–250
- antidepressant “poop-out”, 245
- antidepressant selection
 arousal combos, 365
 based on genetic testing, 361–362
 based on weight of the evidence, 361–362
 breastfeeding patient, 361
 California rocket fuel (SNRI plus mirtazapine), 363
 combination therapies for major depressive disorder, 362–365
 combination therapies for treatment-resistant depression, 362–365
 depression treatment strategy, 284–285
 equipoise situation, 361–362
 evidence-based selection, 353–354
 for pregnant patients, 357–361
 for women based on life-cycle stage, 357
 for women of childbearing age, 357–361
 postpartum patient, 361
 symptom-based approach, 354–357
 triple action combination (SSRI/SNRI/NDRI), 362–363

- antidepressants in development
 CRF1 (corticotrophin-releasing factor) antagonists, 365
 future treatments for mood disorders, 365–366
 glucocorticoid antagonists, 365
 multimodal agents, 365–367
 NMDA blockade, 365–366
 serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs), 365
 triple reuptake inhibitors (TRIs), 365
 vasopressin 1B antagonists, 365
- antihistamines, 335
- antimanic actions
 atypical antipsychotics, 171
- antipsychotics, 47, 129–130
 as mood stabilizers, 373–381
See also atypical antipsychotics; conventional antipsychotics.
- antisocial personality disorder, 574
 aggressive and hostile symptoms, 85
- anxiety disorder treatments, 388
 alpha 2 delta ligands, 403–405
 atypical antipsychotics, 171
 benzodiazepines, 397–403, 414–415
 buspirone, 405–406
 generalized anxiety disorder (GAD), 414–415
 panic disorder, 415–416
 posttraumatic stress disorder (PTSD), 417–419
 social anxiety disorder, 416–417
- anxiety disorders, 268, 290, 327, 385
 blocking reconsolidation of fear memories, 414–415
 COMT genotypes and vulnerability to worry, 395–397
 cortico-striatal-thalamic-cortical (CSTC) feedback loops, 395–397
 fear conditioning, 408–411
 fear extinction, 411–413
 fear response, 392–395
 in children, 386
 noradrenergic hyperactivity in anxiety, 406–410
 overlapping symptoms of anxiety disorders, 391–392
 pain associated with, 427–428
 pain symptoms, 425
 painful physical symptoms, 428
 role of GABA, 397–403
 role of the amygdala, 392–395
 serotonin and anxiety, 405–406
 symptom overlap with major depressive disorder, 389–391
 symptoms, 388–389
 worry circuits, 395–397
- anxious self-punishment and blame in depressive psychosis, 80
- apathy
 in depressive psychosis, 80
- ApoE (apolipoprotein E) and Alzheimer's disease risk, 509–510
- appetite regulation
 neurobiological basis, 564
- aripiprazole, 49–50, 159, 162, 168–169, 171, 300, 383
 metabolic risk, 173
 pharmacologic properties, 202–210
- armodafinil
 in combinations of mood stabilizers, 385
 mode of action, 468
 mood-stabilizing properties, 381
- aromatic amino acid decarboxylase (AAADC), 142
- arousal spectrum, 445
- arson, 85
- asenapine, 48–49, 159, 162, 173
 metabolic risk, 173
 pharmacologic properties, 189–190
- Asendin, 342
- asociality
 in schizophrenia, 82
- aspirin, 340
- atomoxetine, 49, 312
 ADHD treatment, 493–495
- atorvastatin, 49
- ATPase (adenosine triphosphatase), 31
- atropine, 523
- attention deficit hyperactivity disorder (ADHD), 310, 386, 471
 age of onset diagnostic criterion, 484
 aggressive and hostile symptoms, 85
 and neurodevelopment, 480–487
 as a disorder of the prefrontal cortex, 471–475
 as inefficient “tuning” of the prefrontal cortex, 479
 as norepinephrine and dopamine dysregulation in the prefrontal cortex, 475–479
 circuits involved in the brain, 471–475
 comorbidity in adults, 484–487
 environmental factors, 480
 executive dysfunction, 471–474
 impulsive–compulsive dimension, 573
 impulsivity symptom, 475
 in adults, 480–487
 in children and adolescents, 480–487
 inability to focus, 474
 inattention symptom, 471–474
 late-onset type, 484
 selective inattention symptom, 474
 symptoms, 471–475
- attention deficit hyperactivity disorder (ADHD) treatment
 alpha 2A adrenergic agonists, 495–499
 amphetamine, 490–491
 atomoxetine, 493–495
 DAT target for stimulant drugs, 491–496
 differences in children, adolescents and adults, 484–487
 future treatments, 500–502
 general principles of stimulant treatment, 487–490
 methylphenidate, 490
 noradrenergic treatment, 493–500
 slow-release vs fast-release stimulants, 491–496
 stimulants, 490–493
 which symptoms to treat first, 487
- atypical antipsychotics, 49–50, 245
 5HT1A receptor partial agonism, 156–159
 5HT2A receptor antagonism, 142–156
- anticholinergic actions, 173
- antidepressant actions in bipolar and unipolar depression, 169–172
- antihistamine actions, 174
- antimanic actions, 171
- anxiolytic actions, 171
 as mood stabilizers, 380–381
 breastfeeding patient, 386
 cardiometabolic risk, 173–180
 characteristic properties, 141–169
 classification by pharmacologic binding properties, 154–156
 clinical profile, 141
 dopamine D2 receptor partial agonism, 165–169
 effects on 5HT1B/D receptors, 159–160
 effects on 5HT2C receptors, 159–162
 effects on 5HT3 receptors, 162
 effects on 5HT6 receptors, 162
 effects on 5HT7 receptors, 162–165
 effects on dopamine D2 receptors, 150–156
 effects on prolactin levels, 150–151
 link between receptor-binding properties and clinical actions, 169–173
 low extrapyramidal symptoms, 150
 mechanisms of action, 141

Index

- atypical antipsychotics (cont.)
 metabolic disease risk, 173–180
 mitigation of extrapyramidal symptoms, 143–150
 pharmacologic properties of specific drugs, 180–214
 pharmacologic properties of the “dones”, 190–202
 pharmacologic properties of the “pines” (peens), 190
 pharmacologic properties of “two pips and a rip”, 202–211
 pharmacological profile, 141
 relative actions on 5HT_{2A} receptors, 154–156
 relative actions on dopamine D₂ receptors, 154–156
 sedating actions, 171–173
 sedative-hypnotic actions, 171–173
 serotonin–dopamine antagonists, 141
 therapeutic window, 152–154
- atypical antipsychotics in clinical practice, 213–227
 integration with psychotherapy, 226–227
 issues related to switching antipsychotics, 214–220
 treatment resistance, 221–226
 violent and aggressive treatment-resistant patients, 221–226
- atypical depression, 245
- auditory hallucinations in schizophrenia, 81
- autism
 cognitive symptoms, 85
 autism spectrum disorders
 impulsive–compulsive dimension, 574
- autoreceptors
 5HT_{1B/D} receptors, 159–160
 dopamine D₂ receptors, 88
 on monoamine neurons, 8
- Aventyl, 342
- avoidant personality disorder, 245
- avolition
 in schizophrenia, 82
- axoaxonic synapses, 1
 axodendritic synapses, 1
 axosomatic synapses, 1
- bapineuzumab, 521
- barbiturate addiction, 559
- bariatric surgery, 571
- bath salts as synthetic stimulants, 563
- BDNF (brain-derived neurotrophic factor), 290
 effects of depression, 313
 stress effects, 268–269
- behavior
 influence of gene expression, 22–24
- Belviq (lorcaserin), 571
- Benadryl, 459
- benzodiazepine inverse agonists, 67
- benzodiazepine receptors, 6
- benzodiazepines, 5, 335, 341
 as anxiolytics, 397–403, 414–415
 as mood stabilizers, 381, 385
 as PAMS, 403
 as positive allosteric modulators (PAMs), 66
- beta endorphin, 5, 565
- beta secretase inhibitors, 522
- BH₄ (tetrahydrobiopterin), 346
- bifeprunox, 168–169
- binge eating disorder, 564
- biomarkers of Alzheimer's disease, 516–518
- bipolar depression, 237–238
 distinguishing from unipolar depression, 250–252
- bipolar disorder
 affective symptoms, 85
 aggressive and hostile symptoms, 85
 and pregnancy, 385
 antidepressant induced, 382
 comorbid with dementia, 250
 in children and adolescents, 386
 in perimenopausal women, 385
 in women, 385–386
 positive symptoms, 85
 pregnant patient, 385–386
 risk in the postpartum period, 385
 risks with antidepressant treatment, 382
 treatment-resistant affective symptoms, 85
See also mood stabilizers.
- bipolar disorder NOS (not otherwise specified), 243–244
- bipolar I disorder, 238
- bipolar II disorder, 238
- bipolar spectrum, 243–250
 and schizoaffective disorder, 243–247
 bipolar ¼ (0.25) disorder, 245
 bipolar ½ (0.5) disorder, 243–247
 bipolar I ½ (1.5) disorder, 248
 bipolar II ½ (2.5) disorder, 247
 bipolar III (3.0) disorder, 247–250
 bipolar III ½ (3.5) disorder, 251
 bipolar IV (4.0) disorder, 248–252
 bipolar V (5.0) disorder, 248–250
 bipolar VI (6.0) disorder, 250
 schizo-bipolar disorder, 243–247
- bitopertin (RG1678), 232, 234
- BMS-820836 (triple reuptake inhibitor), 365
- body dysmorphic disorder, 575
- borderline personality disorder, 574
 aggressive and hostile symptoms, 85
- Boston bipolar brew (mood stabilizer combination), 385
- botulinum toxin injections, 442
- brain atrophy and depression, 268–269
- brain stimulation
 as antidepressant augmentation, 350–352
- breastfeeding
 prolactin levels during, 95
- breastfeeding patient
 depression treatment, 361
 mood stabilizer selection, 386
- brexpiprazole, 159, 162, 165, 169
 metabolic risk, 173
 pharmacologic properties, 206–210
- brief psychotic disorder, 79, 245
- brompheniramine, 335
- bulimia, 564
- buprenorphine, 547, 560
- bupropion, 298, 551, 564
 formulations, 311
 pharmacologic properties, 309–312
- bupropion/naltrexone (Contrave), 569–571
- buspirone, 159, 346, 405–406, 414
 augmentation of SSRIs, 301–302
- butyrylcholinesterase, 522–525
- caffeine, 47
 mode of action, 469
 wake-promoting agent, 469
- calcineurin, 15
- calcium-calmodulin dependent protein kinases, 16
- calcium channel blockers, 73
- calcium channel blockers (L-type)
 potential mood stabilizers, 379
- calcium second-messenger actions, 15–17
- California careful cocktail (mood stabilizer combination), 385
- California rocket fuel (SNRI plus mirtazapine), 318, 363
- calmodulin, 16
- cAMP (cyclic adenosine monophosphate), 13–15
- cAMP response element-binding protein (CREB), 16–17
- cancer chemotherapy, 162
- cannabinoid 1 receptor (CB₁), 6
- cannabinoid CB₁ receptor antagonists, 559

- cannabinoid receptors, 5–6, 556, 561
 cannabinoids, 442
 cannabis
 and schizophrenia, 114
 effects of, 561
 carbamazepine, 49–50, 340, 373, 384, 386
 in combinations of mood stabilizers, 383
 mood-stabilizing properties, 375–376
 possible mechanisms of action, 376
 side effects, 376
 cardiometabolic risk
 atypical antipsychotics, 173–180
 cariprazine, 159, 169
 metabolic risk, 173
 pharmacologic properties, 209–210
 cataplexy
 GHB treatment, 468
 catatonic depression, 245
 cerevastatin, 49
 cFos gene, 20
 cGMP (cyclic guanosine monophosphate), 6
 chemical neurotransmission, 1
 communication at synapses, 6
 excitation–secretion coupling, 6, 8–9
 genome-to-genome communication, 26–27
 importance in psychopharmacology, 5
 neurotransmitters, 5–6
 postsynaptic neuron, 6
 presynaptic neuron, 6
 role in psychopharmacology, 26
 routes, 27
 sequence, 74–77
 targets for psychotropic drugs, 27
 timescale of events, 27
 chemically addressed nervous system, 5–8
 childhood psychotic disorders
 affective symptoms, 85
 aggressive and hostile symptoms, 85
 positive symptoms, 85
 children
 agoraphobia, 386
 anxiety disorders, 386
 bipolar disorder, 386
 mood-stabilizer selection, 386
 panic disorder, 386
 pediatric mania, 386
 chlomipramine, 342
 chloral hydrate, 559
 chlorpheniramine, 335
 chlorpromazine, 131, 141, 343
 discovery of antipsychotic effects, 131–132
 for obsessive–compulsive disorder (OCD), 575
 for panic disorder, 416
 for PTSD, 418
 for social anxiety disorder, 417
 cognitive remediation psychotherapy, 227
 cognitive symptoms of schizophrenia, 83–85
 community treatment programs, 227
 compulsive eating
 and obesity, 563–573
 compulsive hair pulling (trichotillomania), 575
 compulsive shopping, 575
 compulsive skin picking, 575
 compulsivity
 definition, 537–539
 See also impulsive–compulsive disorders.
 COMT (catechol-*O*-methyltransferase), 86, 257, 348
 genetic variants, 348–350
 genotype and vulnerability to worry, 395–397
 conceptual disorganization
 in disorganized/excited psychosis, 80
 conduct disorder, 386, 574
 conduct disorders in children
 aggressive and hostile symptoms, 85
 constitutive activity
 G-protein-linked receptors, 35
 continuum disease model, 245–247
 Contrave (bupropion/naltrexone), 571
 conventional antipsychotics
 ability to cause neuroleptosis, 131–132
 characteristic properties, 131–141
 differences in side-effect profiles, 139–141
 dilemma of blocking D2 receptors in all dopamine pathways, 136–137
 discovery of chlorpromazine effects, 131–132
 dopamine D2 receptor antagonism, 132–133
 drug-induced parkinsonism, 133–136
 early discoveries, 131
 extrapyramidal symptoms, 133–136
 formulations, 141
 high-potency agents, 141
 histamine H1 receptor blockade, 139–141
 hyperprolactinemia, 136
 list of drugs, 131
 low-potency agents, 141
 muscarinic cholinergic receptor blockade, 137–140
 cholecystokinin, 565
 cholesterol-lowering drugs
 drug interactions, 49
 choline
 presynaptic transporter, 33
 cholinergic deficiency hypothesis of amnesia in dementia, 525
 cholinergic pathways, 524
 cholinergic receptors, 523–528
 cholinesterase inhibitors, 525–527
 chorea, 95
 chromatin
 influence on gene expression, 24
 chronic pain conditions, 420
 association with psychiatric disorders, 422
 effects on brain gray matter, 430–432
 sources of, 420–422
 chronic pain treatment
 descending spinal synapses in the dorsal horn, 432–435
 targeting ancillary symptoms in fibromyalgia, 440–441
 targeting sensitized circuits, 435–441
 chronic widespread pain, 428–429
 circadian rhythms
 disruption in depression, 313–317
 effects of melatonergic hypnotics, 457
 jet lag, 457
 phase advance, 457
 phase delay, 457
 citalopram
 enantiomers, 299
 racemic citalopram, 299–300
 unique properties, 299
 See also escitalopram.
 cJun gene, 20
 classical antipsychotics. *See* conventional antipsychotics.
 clock genes, 313
 clomipramine, 339–340, 343–344
 clonidine, 560
 Clopixol, 131
 clozapine, 48–50, 84, 156, 162, 171, 173–174, 176, 383
 metabolic risk, 173
 pharmacologic properties, 180–182
 club drugs, 563
 Coaxil, 342
 cocaine, 34, 298, 543, 547
 brain's own (dopamine), 543
 cocaine and amphetamine regulated transcripts (CART) peptides, 565
 cocaine vaccine, 547
 codeine, 49, 335, 340
 cognitive behavioral therapy, 226, 353
 for insomnia, 462

Index

- conventional antipsychotics (cont.)
 neuroleptosis caused by, 133
 neuroleptic-induced deficit syndrome, 133
 prolactin elevation, 136
 tardive dyskinesia, 133–136
- cortico-accumbens glutamate pathway, 103
- cortico-brainstem glutamate pathway, 103
- cortico-cortical direct glutamate pathway, 106
- cortico-cortical indirect glutamate pathway, 106
- cortico-striatal glutamate pathway, 103
- cortico-striatal-thalamic-cortical (CSTC) feedback loops, 120
 and anxiety disorders, 395–397
- cortico-thalamic glutamate pathway, 106
- cortisol levels
 fear response, 394
- cortisol secretion
 elevation in depression, 313
- CREB transcription factor activation, 16–17
- crenezumab, 521
- CRF1 (corticotrophin-releasing factor) antagonists, 365
- CS717 (AMPAkine), 500
- CTS21666 (beta secretase inhibitor), 522
- curare, 523
- CX1739 (AMPAkine), 500
- CX516 (AMPAkine), 228
- CX546 (AMPAkine), 228
- CX619 (AMPAkine), 228
- cyamemazine, 131
- cyclobenzaprine, 340
- cyclothymic disorder, 238
- CYP450 (cytochrome P450) enzymes
 and drug interactions, 46–51
 effects of polymorphisms on drug metabolism, 47
 number of, 47
 pharmacokinetic functions, 46–47
 polymorphism, 47
 psychotropic drug targets, 46–51
 role in drug metabolism, 46–47
 using genotypes to predict drug effects, 361
- CYP450 1A2, 47–48
- CYP450 2C19, 47
- CYP450 2D6, 47–49
- CYP450 2D6 polymorphism
 effects on metabolism of
 venlafaxine, 307
- CYP450 3A4, 49–50
- cytokines, 565
- DAO (D-amino acid oxidase), 101, 116
- DAOA (D-amino acid oxidase activator), 101, 116
- DAT. *See* dopamine transporter
- date rape drug
 gamma hydroxybutyrate (GHB), 468, 563
- deacetylation of histones, 24
- decongestants
 interactions with MAOIs, 335
- deep brain stimulation (DBS), 351–352
- delusional disorder, 245
 and psychosis, 79
- delusions, 79
 in schizophrenia, 81
- dementia
 affective symptoms, 85
 aggressive and hostile symptoms, 85
 basis for cholinesterase treatments, 522–528
 causes, 503–505
 cholinergic deficiency hypothesis of
 amnesia in, 525
 clinical features, 503–505
 cognitive symptoms, 85
 diagnosis, 503–505
 nondegenerative dementias, 505
 pathologies, 503–505
 positive symptoms, 85
 treatments for psychiatric and
 behavioral symptoms, 531–533
 with comorbid bipolarity, 250
See also Alzheimer's disease.
- dementia with Lewy bodies, 504
- demethylation of histones, 24
- Depixol, 131
- Deplin, 346
- depression, 237–238, 245
 and MAO-A activity, 331
 and psychosis, 79
 as prodrome of Alzheimer's disease, 518–519
 atypical antipsychotics as
 antidepressants, 169–172
 benefits of early intervention, 289
 brain atrophy and stress, 268–269
 deep brain stimulation (DBS), 351–352
 disease progression concept, 289
 disruption of circadian rhythms, 313–317
 distinguishing unipolar from
 bipolar depression, 250–252
 electroconvulsive therapy (ECT), 350
 in perimenopausal women, 307–308
 monoamine hypothesis of, 262,
 289–290
 monoamine receptor hypothesis
 and gene expression, 262–269
- neurotransmitter receptor
 hypothesis, 290–292
- painful physical symptoms, 428
- physiological effects, 313–317
- symptoms and circuits, 273–278
- transcranial magnetic stimulation (TMS), 350–351
- treatment-resistant affective
 symptoms, 85
- treatment strategy, 284–285
- vulnerability genes, 269–273
See also mood disorders.
- depression treatment
 postpartum depression, 361
 pregnant patient, 357–361
- depression with hypomania, 248–250
- depressive psychosis
 anxious self-punishment
 and blame, 80
 apathy, 80
 psychomotor retardation, 80
- depressive temperament, 238
- Deprimyl, 342
- desensitization
 ligand-gated ion channels, 64–65
- designer drugs, 562
- desipramine, 162, 312, 342–343
- desvenlafaxine, 48
 properties, 307–308
- dex-fenfluramine, 573
- dextromethorphan, 335, 339
 action on NMDA receptors, 366
- DHA (docosahexanoic acid)
 mood-stabilizing properties, 381
- diabetic ketoacidosis
 risk with atypical antipsychotics,
 178–179
- diabetic peripheral neuropathic pain,
 425
- diagnosis in psychiatry
 use of Research Domain Criteria, 474
- diazepam, 5
- dichotomous disease model, 243–245
- diethylpropion, 573
- dihydrofolate, 346
- dihydropyridine calcium channel
 blockers, 73
- diphenhydramine, 459–460
- DISC-1 (disrupted in schizophrenia)
 gene, 115–121
- disease progression in major
 depression, 289
- disorganized/excited psychosis
 conceptual disorganization, 80
 disorientation, 80
 excitement, 80
- disorientation
 in disorganized/excited
 psychosis, 80

- disulfiram, 559
 DMT (dimethyltryptamine), 562
 DNA
 function of “junk DNA”, 18
 gene regulatory sections, 18
 number of genes contained in, 18
 DNA demethylases, 24
 DNA methylation, 24
 DNA methyltransferases (DNMT), 24
 DNA transcription, 18
 DNMT1 (DNA methyltransferase 1), 26
 DNMT2 (DNA methyltransferase 2), 26
 DNMT3 (DNA methyltransferase 3), 26
 Dolmatil, 131
 DOM (2,5-dimethoxy-4-methylamphetamine), 562
 donepezil, 529
 “dones”, 154, 162
 pharmacologic properties, 202
 dopa decarboxylase, 86, 257
 dopamine, 5, 237
 as brain's own cocaine/amphetamine, 543
 as neurotransmitter of hedonic pleasure, 542–543
 norepinephrine precursor, 257
 volume neurotransmission, 8
 dopamine beta hydroxylase, 257
 dopamine D2 receptor antagonists
 conventional antipsychotics, 132–133
 effects of D2 receptor blockade, 133–137
 dopamine D2 receptor partial agonists
 atypical antipsychotics, 165–169
 dopamine D2 receptors, 86–89
 effects of atypical antipsychotics, 150–156
 dopamine hypothesis of
 schizophrenia, 86, 89–96
 linking with the NMDA receptor hypofunction hypothesis, 111–113
 dopamine pathways, 91
 mesocortical dopamine pathway, 92–94
 mesolimbic dopamine pathway, 89–92, 94–95
 nigrostriatal dopamine pathway, 95
 thalamic dopamine pathway, 96
 tuberoinfundibular dopamine pathway, 95
 dopamine receptors, 86–89
 dopamine reuptake transporter pumps, 8
 dopamine transporter (DAT), 8, 86
 psychotropic drug target, 29–32
 target for stimulants in ADHD, 491–496
 dopamine vesicular transporter, 29
 dopaminergic neurons, 86–89
 DORA 1, 464
 DORA 5, 464
 DORA 22, 464
 DORAs (dual orexin receptor antagonists), 463–464
 dorsolateral prefrontal cortex (DLPFC), 122
 in schizophrenia, 122–126
 dothiapin, 342
 doxepin, 342, 461
 doxylamine, 459
 drug abuse
 aggressive and hostile symptoms, 85
 drug abuse treatment, 463
 drug addiction.
 See impulsive–compulsive disorders; substance addictions.
 drug-induced parkinsonism, 133–136
 drug-induced psychosis, 574
 positive symptoms, 85
 drug-induced psychotic disorder and psychosis, 79
 drug interactions
 and CYP450 enzymes, 46–51
 drug metabolism
 role of CYP450 (cytochrome P450) enzymes, 46–47
 drugs
 actions on neurotransmission, 5–6
 similarities to natural neurotransmitters, 5–6
 drugs of abuse, 339
 stimulants, 491–492
 D-serine. *See* serine.
 DSM (Diagnostic and Statistical Manual), x, 79
 psychosis, 79
 Research Domain Criteria, x
 dual orexin receptor antagonists (DORAs), 463–464
 duloxetine, 48
 properties, 308–309
 dysbindin gene, 115–121
 dyskinesias, 95
 dyssocial personality disorder, 574
 dysthymia, 238
 dystonia, 95
 eating disorders, 290, 385, 563
 “ecstasy” (MDMA), 30, 562
 edivoxetine
 norepinephrine reuptake inhibitor (NERI), 313
 Elavil, 6, 342
 electroconvulsive therapy (ECT)
 use in depression, 350
 EMPA (SORA-2 agent), 464
 employment
 help with, 227
 Endep, 342
 endocannabinoids (“endogenous marijuana”), 6
 endophenotypes
 compulsivity, 539
 impulsivity, 539
 endorphins, 559
 as brain's own morphine/heroin, 543
 enkephalins, 559
 enzyme inhibitors, 43–45
 enzymes
 irreversible inhibition, 43–45
 psychotropic drug targets, 43–51
 reversible inhibition, 43–45
 EPA (eicosapentanoic acid)
 mood-stabilizing properties, 381
 ephedrine, 573
 epigenetics, 24–26
 and gene expression, 24
 and schizophrenia, 114–115
 definition, 24
 effects of psychotherapy, 352–353
 influence on the status quo of a cell, 26
 molecular mechanisms of gene regulation, 24
 epistasis, 348–350
 neuroimaging in schizophrenia, 126–128
 Epworth Sleepiness Scale, 465
 ErbB4 gene, 115–121
 ERK (extracellular signal regulated kinase), 18
 ERK/AKT signal transduction cascade, 366
 erythromycin (antibiotic), 49
 escitalopram
 unique properties, 300
 eslicarbazepine
 potential mood stabilizer, 377–379
 estrogen replacement therapy (ERT), 307, 361
 eszopiclone, 341, 453, 455
 ethchlorvynol, 559
 ethinamate, 559
 euthymia, 238
 excessive daytime sleepiness
 causes and consequences, 465
 mechanism of action of wake-promoting agents, 466–469
 problems with cognitive performance, 465–466

Index

- excitation–secretion coupling, 6, 8–9
 excitatory amino acid transporter (EAAT), 96, 101
 excitatory amino acid transporters 1–5 (EAAT1–5), 33
 excitement
 in disorganized/excited psychosis, 80
 experience-dependent development of synapses, 114–115
 extrapyramidal nervous system, 95
- family support, 227
 fear conditioning, 408–411
 role of the amygdala, 409–411
 fear extinction, 411–413
 fear memories
 blocking reconsolidation of, 414–415
 fenfluramine, 573
 fibromyalgia, 425, 428–431
 milnacipran treatment, 309
 off-label use of GHB, 468
 targeting ancillary symptoms, 440–441
 first-generation antipsychotics.
 See conventional antipsychotics
 flashbacks, 406
 flumazenil, 403
 fluoxetine, 6, 31, 49, 162, 182, 313, 340
 5HT_{2C} antagonist properties, 297
 combined with olanzapine, 162
 unique properties, 297
 flupenthixol, 131
 fluphenazine, 131
 fluvastatin, 49
 fluvoxamine, 48–49
 sigma 1 receptor binding, 299
 unique properties, 299
 fMRI
 imaging circuits in schizophrenia, 120–126
 folate, 346, 348, 382
 food addiction, 563–564
 Fos protein, 20–21
 “Foxy” (5-methoxy-diisopropyltryptamine), 562
 frontotemporal dementia
 cognitive symptoms, 85
- G-protein-linked receptors
 activity in absence of agonists, 35
 agonist action, 35–36
 agonist spectrum, 35–43
 antagonist action, 36–37
 constitutive activity, 35
 inverse agonist action, 42–43
 partial agonist action, 37–42
 pharmacologic subtypes, 35–43
 psychotropic drug targets, 35–43
 silent antagonists, 36–37
 structure and function, 34–35
 G-protein-linked signal transduction
 cascades, 11
 activation of CREB, 16–17
 influence on gene expression, 16–17
 phosphoprotein messengers, 13–16
 second messengers, 11–13
 G proteins, 17
 GABA (gamma aminobutyric acid), 5
 binding to GABA_A sites, 66
 effects of benzodiazepines, 66
 role in anxiety disorders, 397–403
 synthesis and storage, 397
 GABA_A positive allosteric modulators (PAMs), 453
 and psychiatric insomnia, 455–459
 insomnia treatment, 454–455
 GABA receptors, 397–403
 GABA transaminase, 397
 GABA transporter (GAT), 397
 GABA transporters, 33, 397–399
 GABA vesicular transporter, 34
 gabapentin, 71, 384–385, 403–405, 414, 437
 properties, 379
 galactorrhea, 95
 galanin, 565
 galantamine, 524, 527
 Gamanil, 342
 gambling disorder, 573
 gamma hydroxybutyrate (GHB), 563
 abuse potential, 468
 date rape drug, 468
 performance-enhancing drug, 468
 wake-promoting agent, 468–470
 gamma secretase inhibitors, 521–522
 GAT1 transporter, 33
 gate theory of pain, 425
 gene effects
 neuroimaging in schizophrenia, 126–128
 gene expression
 and epigenetics, 24
 consequences of epigenetic influences, 26
 effects of signal transduction cascades, 16–18
 functions affected by, 18
 influence of behavior on, 22–24
 influence on behavior, 22–24
 molecular mechanism, 18–24
 molecular mechanisms of epigenetics, 24
 regulatory sections of DNA, 18
 result of neurotransmission, 18–24
 role of chromatin, 24
 triggered by phosphoprotein cascade, 16–18
 gene transcription, 18–20
 generalized anxiety disorder (GAD), 405
 treatments, 414–415
 genes
 coding region, 18
 immediate early genes, 20–21
 late gene activation, 20–22
 number in the human genome, 18
 regulatory region, 18–20
 genetic testing
 aid to antidepressant selection, 361–362
 genomes of neurons
 communication between, 9–10
 ghrelin, 565
 glucagon, 565
 glucocorticoid antagonists, 365
 glucocorticoid levels
 effects of stress, 268–269
 glutamate, 5
 target in Alzheimer's disease, 527–531
 glutamate hypothesis of cognitive deficiency in Alzheimer's disease, 527–534
 glutamate pathways
 cortico-accumbens, 103
 cortico-brainstem, 103
 cortico-cortical (direct), 106
 cortico-cortical (indirect), 106
 cortico-striatal, 103
 cortico-thalamic, 106
 hippocampal-accumbens, 105
 thalamo-cortical, 106
 glutamate receptors, 101–102
 subtypes, 56
 glutamate synthesis, 96
 glutamate transporters, 33
 glutaminase, 96
 glutamine synthetase, 96
 glutamine transporter, 96–98
 glutethimide, 559
 glycine agonists, 228
 glycine synthesis, 96–101
 glycine transporters, 33
 GlyT1 inhibitors, 232–234
 grandiose expansiveness
 in paranoid psychosis, 80
 GSK (glycogen synthase kinase), 46
 GSK3 (glycogen synthase kinase 3), 18
 GSK3 (glycogen synthase kinase 3) inhibitors, 46
 GSK372475 (triple reuptake inhibitor), 365
- habits
 as compulsive behavior, 539–541
 as conditioned responses, 539–541

- Haldol, 131
 hallucinations, 79–80
 in schizophrenia, 81
 hallucinogen addictions, 561–563
 haloperidol, 131, 141
 hedonic pleasure center
 mesolimbic dopamine pathway,
 542–543
 heroin, 559
 brain's own (endorphins), 543
 herpes zoster (shingles), 425
 high-affinity glutamate
 transporters, 29
 hippocampal-accumbens glutamate
 pathway, 105
 hippocampus
 dysfunction in schizophrenia, 123
 effects of stress, 268–269
 histamine, 5
 and the sleep/wake switch, 450–453
 mechanisms of inactivation, 33
 vesicular transporter, 29
 histamine H1 receptor antagonists,
 318
 as hypnotics, 459–461
 atypical antipsychotics, 174
 histamine H1 receptors, 450–451
 blockade by conventional
 antipsychotics, 139–141
 histamine H2 receptors, 452
 histamine H3 receptor
 antagonists, 500
 histamine H3 receptors, 452
 histamine H4 receptors, 452
 histamine receptors
 NMDA receptors, 452
 histone acetylation, 24
 histone deacetylases (HDACs), 24, 26
 histone demethylases, 24
 histone methylation, 24
 histone methyltransferases, 24
 histones deacetylation, 24
 HIV/AIDS
 protease inhibitors, 49
 reverse transcriptase inhibitors, 49
 HMG-CoA reductase inhibitors, 49
 hoarding behavior, 575
 homocysteine, 348
 hormone-linked signal transduction
 cascades, 11
 influence on gene expression, 17
 phosphoprotein messengers, 16
 second messengers, 11
 hormone response elements (HREs), 17
 hormones, 5
 hostile belligerence
 in paranoid psychosis, 80
 hostile symptoms
 disorders associated with, 85
 HPA (hypothalamic-pituitary-
 adrenal) axis, 365
 abnormalities in depression, 313
 abnormalities related to stress, 431
 effects of stress, 268–269
 fear response, 394
 HT0712 (PDE4 inhibitor), 500
 human genome
 number of genes, 18
 Hunter Serotonin Toxicity Criteria, 335
 hydrocodone, 340, 559
 hyperalgesia, 425
 hyperarousal states, 406
 hyperglycemic hyperosmolar
 syndrome
 risk with atypical antipsychotics,
 178–179
 hyperkinetic movement disorders, 95
 hyperprolactinemia, 136, 150–151
 hypersexual disorder, 573
 hypersomnia
 causes and consequences, 465
 mechanism of action of wake-
 promoting agents, 466–469
 problems associated with sleep
 deprivation, 465
 problems with cognitive
 performance, 465–466
 treatments, 445
 hyperthymic temperament, 238
 and mood disorders, 248–252
 hypochondriasis, 575
 hypomania, 238
 antidepressant induced, 382
 with depression, 248–250
 hypothalamus
 role in appetite regulation, 564
 ICD (International Classification of
 Diseases), x, 79
 psychosis, 79
 iloperidone, 49–50, 159, 162, 173–174,
 383
 metabolic risk, 173
 pharmacologic properties, 197–199
 imipramine, 162, 342
 immediate early genes, 20–21
 impulse control disorders
 aggressive and hostile symptoms, 85
 impulsive-compulsive disorders
 aggression and violence in
 psychiatric disorders, 574
 behavior disorders, 573–575
 bottom-up compulsive dorsal
 striatal drives, 539–541
 bottom-up impulsive ventral striatal
 drives, 539–541
 compulsion development in drug
 addiction, 541–542
 compulsivity endophenotype, 539
 definition of compulsivity, 537–539
 definition of impulsivity, 537–539
 eating disorders, 563–573
 endophenotypes, 539
 habit formation, 541–542
 habits, 539–541
 hypothetical shared neurobiology,
 537
 impulsivity endophenotype, 539
 mesolimbic dopamine circuit as
 pathway of reward, 542–543
 neurocircuitry involved, 539–543
 obesity as, 563–573
 obsessive-compulsive disorder
 (OCD), 574–575
 range of disorders, 537–538
 stimulant addiction process,
 543–547
 substance addictions, 543–563
 therapeutic challenge, 537
 top-down prefrontal cortical
 inhibition, 539–541
 ventral to dorsal migration of
 response, 541–543
 impulsivity
 definition, 539
 in psychiatric conditions, 475
 inactivation
 ligand-gated ion channels, 64–65
 indole-alkylamines, 562
 inhalants as drugs of abuse, 563
 inositol
 mood-stabilizing properties, 381
 insomnia
 and slow-wave sleep, 463
 caused by restless legs syndrome
 (RLS), 462
 causes, 452
 definitions, 452
 insomnia treatment, 444
 alpha 2 delta ligands, 462
 behavioral treatments, 462
 benzodiazepine hypnotics, 452–455
 chronic treatment for chronic
 insomnia, 452–457
 cognitive behavioral therapy, 462
 dopamine agonists, 462
 doxepin, 461
 dual orexin receptor antagonists
 (DORAs), 463–464
 GABA_A positive allosteric
 modulators (PAMs), 453–455
 histamine H1 receptor antagonists
 as hypnotics, 459–461
 long-term use of hypnotics,
 452–453
 melatonergic hypnotics, 457
 orexin antagonists, 463–465

Index

- insomnia treatment (cont.)
 psychiatric insomnia and
 GABA_A PAMs, 455–459
 serotonergic hypnotics, 457–458
 single orexin receptor antagonists
 (SORAs), 463–464
 sleep hygiene, 462
 trazodone, 457–458
 Z-drugs, 453–455
- insulin, 565
- intermittent explosive disorder, 574
- Internet addiction, 573
- interpersonal therapy, 353
- intravenous immunoglobulin (IVIG)
 Alzheimer's disease trials, 521
- inverse agonist action
 G-protein-linked receptors, 42–43
 ligand-gated ion channels, 61–63
- ion-channel-linked receptors, 52–53
See also ligand-gated ion channels.
- ion-channel-linked signal
 transduction cascades, 11
 activation of CREB, 16–17
 influence on gene expression, 16–17
 phosphoprotein messengers, 13–16
 second messengers, 11
- ion channels
 coordination during
 neurotransmission, 74–77
 functions of, 52
 major types, 52
 psychotropic drug targets, 52
See also ligand-gated ion channels;
 voltage-gated ion channels.
- ionotropic receptors, 52–53
See also ligand-gated ion channels.
- iproniazid, 326
- isocarboxazid, 327
- jet lag, 457
- JNJ10394049 (SORA-2 agent), 464
- JNJ17305600 (GlyT1 inhibitor), 232
- Jun protein, 20–21
- kainate receptors, 101–102
- ketamine, 67, 107–108, 350, 563
 antidepressant effects, 365–366
- ketoconazole (antifungal drug), 49
- kinases, 11, 13–18
- kleptomania, 573
- Kraepelin, Emil, 243
- Lami-quel mood-stabilizer
 combination, 385
- lamotrigine, 341, 383–384, 386
 in combinations of mood stabilizers,
 383, 385
 mechanism of action, 376–377
 mood-stabilizing properties, 376–377
- rashes caused by, 376
 tolerability profile, 376
- leptin, 565
- leucine zipper type of transcription
 factor, 20–21
- levetiracetam, 34, 384
- levodopa, 327
- Lewy body dementia
 cognitive symptoms, 85
- licarbazepine, 377, 384
- ligand-gated ion channels, 52
 adaptive states, 64–65
 agonist spectrum, 56–64
 allosteric modulation, 65–67
 AMPA subtype, 56
 antagonist action, 57–59
 desensitization, 64–65
 different receptor states, 64–65
 full agonist action, 56
 glutamate receptors, 56
 inactivation, 64–65
 inverse agonist action, 61–63
 negative allosteric modulators
 (NAMs), 65–67
 nicotinic cholinergic receptors, 65
 NMDA subtype, 56
 partial agonist action, 58–61
 pentameric subtypes, 54–56
 positive allosteric modulators
 (PAMs), 65–67
 psychotropic drug targets, 54
 regulation of opening and closing,
 52–53
 structure and function, 54–57
 tetrameric subtypes, 56
- lithium, 46, 339, 346, 386
 and Alzheimer's disease, 372
 effects on suicidality, 372
 for mild mania, 383
 in combinations of mood stabilizers,
 383
 mood-stabilizing properties,
 371–373
 plus valproate, 374
 possible mechanisms of action,
 371–372
 side effects, 372–373
- locus coeruleus, 394, 463
- lofepramine, 342
- lorcaserin, 159
- lorcaserin (Belviq), 571
- Loroxyl, 342
- Lou Gehrig's disease, 380
- lovastatin, 49
- low back pain, 425, 431
- loxapine, 131
- Loxitane, 131
- LSD (D-lysergic acid diethylamide),
 562
- LuAA21004. *See* vortioxetine.
- LuAA24530 (triple reuptake
 inhibitor), 365
- Ludiomil, 342
- lurasidone, 49–50, 159, 162, 165,
 381, 383
 in combinations of mood
 stabilizers, 385
 metabolic risk, 173
 pharmacologic properties, 199–202
- LY2140023 (mGluR presynaptic
 antagonist/postsynaptic
 agonist), 228
- LY293558 (AMPAkinase), 228
- LY450139 (semagacestat), 521–522
- LY451395 (AMPAkinase), 500
- major depressive disorder, 165, 238,
 248
 affective symptoms, 85
 as prodrome of Alzheimer's disease,
 518–519
 disease progression concept, 289
 in perimenopausal women, 307–308
 symptom overlap with anxiety
 disorders, 389–391
 use of combination antidepressant
 therapies, 362–365
- mania, 237–238, 245
 and psychosis, 79
 antidepressant induced, 382
 antimanic actions of atypical
 antipsychotics, 171
 in children and adolescents, 386
 mild mania, 383
 symptoms and circuits, 278–279
See also mood disorders.
- MAO. *See* monoamine oxidase.
- MAOIs. *See* monoamine oxidase
 inhibitors.
- MAPK (MAP kinase, mitogen
 activated protein kinase), 18
- maprotiline, 312, 342–343
- marijuana, 5
 and schizophrenia, 114
 brain's own (anandamide), 543
 effect on appetite, 564
 effects of, 561
- MC4R agonists, 571
- MDMA (3,4-methylene-
 dioxymethamphetamine), 30, 562
- meclobemide, 333
- mehylone, 563
- MEK (MAP kinase/ERK kinase or
 mitogen-activated protein kinase
 kinase/extracellular signal-
 regulated kinase kinase), 17
- melancholic depression, 245
- melanin-concentrating hormone, 565

- melanocyte 4 receptors (MC4Rs), 565
 melatonegic hypnotics, 457
 melatonin, 457
 melatonin secretion
 and depression, 313–317
 Mellaril, 131
 memantine, 527–531
 memory disturbance. *See* dementia.
 meperidine, 339–340
 mephedrone, 563
 mescaline, 562
 mesolimbic dopamine circuit
 pathway of reward in
 impulsive–compulsive disorders,
 542–543
 mesoridazine, 131
 metabolic disease risk
 atypical antipsychotics, 173–180
 metabotropic glutamate receptors
 (mGluRs)
 presynaptic antagonists/
 postsynaptic agonists, 228
 metformin, 571
 methadone, 340, 560
 methionine synthase, 348
 methionine synthase reductase, 348
 methylation of histones, 24
 methylenedioxypyrovalerone
 (MDPV), 563
 methylenetetrahydrofolate reductase
 genetic variants, 348–350
 L-methylfolate, 24, 346–350
 mood-stabilizing properties, 382
 methylphenidate, 34, 298, 547
 ADHD treatment, 490
 wake-promoting agent, 468
 methyltransferases, 24
 methyprylon, 559
 mianserin, 162, 318–322
 mild cognitive impairment (MCI)
 distinction from normal aging,
 515–519
 milnacipran
 properties, 309
 mirtazapine, 159, 162, 171, 176, 313,
 318–322, 460
 California rocket fuel (SNRI plus
 mirtazapine), 318, 363
 mitochondria, 257
 mivacurium, 335
 mixed state mood disorders, 238, 245
 antidepressant induced, 382
 MK-4305 (suvorexant), 463–464
 MK-6096, 464
 modafinil
 mode of action, 466–468
 mood-stabilizing properties, 381
 monoamine hypothesis of depression,
 262, 289–290
 monoamine neurons
 volume neurotransmission at
 autoreceptors, 8
 monoamine neurotransmitters
 and mood disorders, 237
 monoamine oxidase (MAO), 46
 monoamine oxidase A (MAO-A), 86,
 142, 257, 327–331
 and depression, 331
 reversible inhibitors of MAO-A
 (RIMAs), 333–335
 monoamine oxidase B (MAO-B), 86,
 142, 257, 327–331
 monoamine oxidase inhibitors
 (MAOIs), 326–342
 avoidance of serotonergic agents,
 335–339
 clinical management solutions,
 331–342
 dietary tyramine interaction,
 331–335
 drug–drug interactions, 335–340
 interactions with analgesics, 340
 interactions with anesthetics, 335
 interactions with decongestants,
 335
 interactions with opiates, 340
 interactions with tricyclic
 antidepressants, 339–340
 MAO-A activity and depression,
 331
 MAO subtypes, 327–331
 myths and misinformation,
 331–340
 reversible inhibitors of MAO-A
 (RIMAs), 333–335
 risk of hypertensive crisis, 331–335
 risk of serotonin toxicity/serotonin
 syndrome, 335–339
 switching to and from, 340–342
 sympathomimetics to avoid or
 administer with caution, 335
 monoamine receptor hypothesis of
 depression
 and gene expression, 262–269
 monoamine transporter blockers,
 289–346
 monoamine transporters (SLC6
 family)
 psychotropic drug targets, 29–32
 monoamines
 interactions between, 262
 mood disorders, 237
 affective symptoms of
 schizophrenia, 82–84
 and hyperthymic temperament,
 248–252
 and monoamine neurotransmitters,
 237
 bipolar depression, 237–238
 bipolar disorder NOS (not
 otherwise specified), 243–244
 bipolar spectrum, 243–250
 bipolar ¼ (0.25) disorder, 245
 bipolar ½ (0.5) disorder, 243–247
 bipolar I disorder, 238
 bipolar I ½ (1.5) disorder, 248
 bipolar II disorder, 238
 bipolar II ½ (2.5) disorder, 247
 bipolar III (3.0) disorder, 247–250
 bipolar III ½ (3.5) disorder, 251
 bipolar IV (4.0) disorder, 248–252
 bipolar V (5.0) disorder, 248–250
 bipolar VI (6.0) disorder, 250
 bipolarity comorbid with
 dementia, 250
 caused by antidepressants, 247–250
 continuum disease model, 245–247
 cyclothymic disorder, 238, 247
 depression, 237–238
 depression symptoms and circuits,
 273–278
 depression with hypomania, 248–250
 depressive temperament, 238
 description, 237–238
 dichotomous disease model, 243–245
 distinguishing unipolar from
 bipolar depression, 250–252
 double depression, 238
 dysthymia, 238
 future treatments, 365–366
 hyperthymic temperament, 238
 hypomania, 238
 major depressive disorder, 238, 248
 mania, 237–238
 mania symptoms and circuits,
 278–279
 mild mania, 383
 mixed mood state, 238
 monoamine hypothesis of
 depression, 262
 monoamine receptor hypothesis
 and gene expression, 262–269
 mood-centered perspective, 244
 mood chart, 238
 mood-related temperaments, 238
 natural history, 252–253
 neuroimaging, 280–281
 neurotransmitter systems
 involved, 255
 pain associated with, 427–428
 pain symptoms, 425
 question of progression, 252–253
 range of moods, 238
 rapid cycling, 238
 related to substance abuse, 251
 relationship to psychotic disorders,
 243–247

Index

- mood disorders (cont.)
 schizoaffective disorder, 243–247
 schizo-bipolar disorder, 243–247
 stress and depression, 268–273
 unipolar depression, 237–238
- mood stabilizer selection, 382–386
- adolescents, 386
- benzodiazepines, 385
- Boston bipolar brew, 385
- breastfeeding patient, 386
- California careful cocktail, 385
- carbamazepine combinations, 383
- children, 386
- combinations of mood stabilizers, 383–385
- first-line treatments in bipolar disorder, 383
- innovative “eminence-based” combinations, 385
- Lami-quel combination, 385
- lamotrigine combinations, 383, 385
- lithium combinations, 383
- monotherapy trials, 382–383
- pregnant patient, 385–386
- quetiapine combinations, 385
- Tennessee mood shine, 385
- valproate combinations, 383
- women and bipolar disorder, 385–386
- mood stabilizers
- anticonvulsants, 373–380
- antipsychotics, 373–381
- armodafinil, 381
- atypical antipsychotics, 380–381
- benzodiazepines, 381
- definitions, 370–371
- future developments, 387
- inositol, 381
- lithium, 371–373
- L-methylfolate, 382
- modafinil, 381
- omega-3 fatty acids (EPA and DHA), 381
- risks related to antidepressants, 382
- thyroid hormones, 382
- morphine, 5, 335
- brain's own (endorphins), 543
- motivational therapies, 227
- motor disturbances in psychosis, 80
- motor hyperactivity, 474
- mRNA, 18
- mTOR (mammalian target of rapamycin) pathway, 366
- multi-infarct dementia
- cognitive symptoms, 85
- muscarine, 523
- muscarinic cholinergic receptors, 137–140
- blockade by conventional antipsychotics, 137–140
- nalmefene, 559
- naloxone, 560
- naltrexone, 385, 417, 547, 556, 560, 564
- bupropion/naltrexone (Contrave), 569–571
- NAMs (negative allosteric modulators), 65–67
- narcolepsy, 463–464
- GHB treatment, 468
- Navane, 131
- nefazodone, 49, 322
- negative allosteric modulators (NAMs), 65–67
- nerve growth factor (NGF), 6
- NET. *See* norepinephrine transporter.
- neuregulin gene, 115–121
- neurodegenerative disorders, 327–329
- neurodevelopment
- and ADHD, 480–487
- neuroimaging
- Alzheimer's disease biomarkers, 517–518
- circuits in schizophrenia, 120–126
- epistasis in schizophrenia, 126–128
- gene effects in schizophrenia, 126–128
- mood disorders, 280–281
- neuroleptic-induced deficit syndrome, 133
- neuroleptic-induced tardive dyskinesia, 95
- neuroleptic malignant syndrome, 136
- neuroleptics, 131–132
- neuron genomes
- communication between, 9–10
- neuronal circuits, 6
- neurons
- autoreceptors, 8
- dysconnectivity in schizophrenia, 114–120
- effects of malfunction, 2
- excitation–secretion coupling, 8–9
- functional alteration by drugs, 2
- general structure of a neuron, 2
- inputs from neuronal circuits, 6
- inputs involving neurotransmitters, 6
- nature of, 1–2
- number in the human brain, 1–2
- synapses, 1
- neuropeptide Y, 565
- neuropeptides, 5
- mechanisms of inactivation, 33
- neurotransmission
- anatomical basis, 1–2
- chemical basis, 5
- classical type, 6
- nonsynaptic diffusion type, 6–8
- retrograde (reverse) type, 6
- signal transduction cascades, 9–24
- target for drug actions, 5–6
- trigger for gene expression, 18–24
- volume type, 6–8
- See also* chemical neurotransmission.
- neurotransmitter receptor hypothesis
- of depression, 290–292
- neurotransmitter transport
- presynaptic reuptake, 28–29
- sodium pump, 30–31
- vesicular storage, 28–29
- neurotransmitter transporters
- high-affinity glutamate transporters, 29
- intracellular synaptic vesicle transporters, 29–32
- plasma membrane transporters, 29–30
- psychotropic drug targets, 28–34
- SLC1 gene family, 29–30
- SLC6 gene family, 29–30
- sodium/chloride-coupled transporters, 29
- neurotransmitters, 5–6
- as first messengers, 10
- inputs to neurons, 6
- location in synapses, 1
- retrograde neurotransmitters, 6
- similarities of drugs to, 5–6
- neurotrophic factors
- retrograde neurotransmitters, 6
- neurotrophin-linked signal transduction cascades, 11
- influence on gene expression, 17–18
- phosphoprotein messengers, 13–16
- second messengers, 11
- nicotine, 523–524
- brain's own (acetylcholine), 543
- effect on appetite, 564
- effect on nicotinic cholinergic receptors, 65
- nicotine addiction, 311, 547–553
- nicotine dependence, 487
- nicotinic cholinergic receptors, 523–524
- desensitization, 65
- effects of nicotine, 65
- positive allosteric modulators (PAMs), 524
- nicotinic receptor agonists, 500
- nightmares, 406
- nigrostriatal dopamine pathway, 95, 139
- nitric oxide (NO)
- retrograde neurotransmitter, 6
- NMDA antagonists, 442
- NMDA blockade
- potential treatment for mood disorders, 365–366

- NMDA neurotransmission, 232
 NMDA receptor hypofunction
 hypothesis of schizophrenia, 107–111
 linking with the dopamine hypothesis, 111–113
 NMDA receptors, 99–102, 234
 negative allosteric modulators (NAMs), 67
 nonspecific cholinesterase, 522–525
 nonsteroidal anti-inflammatory drugs, 340
 nonsynaptic diffusion
 neurotransmission, 6–8
 noradrenaline. *See* norepinephrine.
 noradrenergic hyperactivity in anxiety, 406–410
 noradrenergic neurons, 255–262
 norepinephrine, 5, 237
 regulation of 5HT release, 262
 norepinephrine dopamine reuptake inhibitors (NDRIs), 309–312
 in triple action combination (SSRI/SNRI/NDRI), 362–363
 norepinephrine receptors, 258–262
 norepinephrine reuptake inhibitors (NERIs)
 edivoxetine, 313
 See also selective norepinephrine reuptake inhibitors (NRIs).
 norepinephrine reuptake pump.
 See norepinephrine transporter
 norepinephrine transporter (NET), 86, 257–258
 psychotropic drug target, 29–32
 See also SNRIs, 306
 norepinephrine transporter (NET) inhibition
 selective NRIs, 312–313
 norepinephrine vesicular transporter, 29
 norfluoxetine, 49, 341
 Norpramin, 342
 norquetiapine, 183–185
 nortriptyline, 342–343
 nucleosomes, 24
 nucleus accumbens, 542
 Nuvigil, 468
- obesity
 and food addiction, 563–564
 as an impulsive–compulsive disorder, 573
 neurobiology of appetite regulation, 564
 role of the hypothalamus in appetite regulation, 564
 obesity treatment, 566–573
 bariatric surgery, 571
- bupropion/naltrexone (Contrave), 569–571
 lorcaserin (Belviq), 571
 MC4R agonists, 571
 metformin, 571
 orlistat, 571
 phentermine/topiramate ER (Qsmia), 566–569
 role of 5HT2C receptors, 159
 tasofensine, 571
 zonisamide, 571
- obsessive–compulsive disorder (OCD), 299, 346, 574–575
 cognitive behavioral therapy, 575
- olanzapine, 48, 159, 162, 173–174, 176, 313
 5HT2C antagonist, 162
 combined with fluoxetine, 162
 metabolic risk, 173
 pharmacologic properties, 182–183
- omega-3 fatty acids (EPA and DHA)
 mood-stabilizing properties, 381
- OPC4392 (D2 partial agonist), 168
- opiate addictions, 559–561
 opiate antagonists, 559
- opiates
 interactions with MAOIs, 340
 withdrawal syndrome, 560
- opioids
 interaction with MAOIs, 339
 oppositional defiant disorder, 574
- Orap, 131
- orbital frontal cortex
 link with impulsivity, 475
- orexin, 565
 orexin 1 receptors, 463–464
 orexin 2 receptors, 463–464
 orexin A, 463
 orexin antagonists, 463–465
 orexin B, 463
- Org 24292 (AMPAkine), 228
 Org 24448 (AMPAkine), 228
 Org 25271 (AMPAkine), 228
 Org 25501 (AMPAkine), 228
 Org 25573 (AMPAkine), 228
 Org-25935/SCH-900435 (GlyT1 inhibitor), 232
- orlistat, 571
 osteoarthritis, 425
 oxcarbazepine, 340, 384
 potential mood stabilizer, 377–379
- oxycodone, 559
- pain
 activation of nociceptive nerve fibers, 422–423
 allodynia, 425
 as a psychiatric “vital sign”, 422, 441
- associated with anxiety disorders, 427–428
 associated with mood disorders, 427–428
 association with psychiatric disorders, 422
 central mechanisms in neuropathic pain, 425–428
 central pain, 421–422
 definitions, 420
 definitions of pain states, 421
 functions of, 420
 gate theory of pain, 425
 hyperalgesia, 425
 in the presence of emotional symptoms, 427–428
 low back pain treatment, 346
 neuropathic pain, 423–426
 nociceptive pathway, 422–423
 “normal” pain, 423
 peripheral mechanisms in neuropathic pain, 425
 peripheral pain, 422
 psychic pain, 308–309
 segmental central sensitization, 425
 somatic pain, 308–309
 sources of chronic pain conditions, 420–422
 suprasegmental central sensitization, 425–428, 431
 “wind-up” response, 425
 See also chronic pain conditions.
- pain syndromes
 fibromyalgia, 429–430
- pain treatments, 429
 duloxetine, 308–309
- paliperidone, 48, 162
 metabolic risk, 173
 pharmacologic properties, 194–196
- Pamelor, 342
- PAMs. *See* positive allosteric modulators
- panic attacks, 346, 394, 406, 412
 treatments, 415–416
- panic disorder, 327, 405
 in children, 386
 treatments, 415–416
- paranoid personality disorder, 245
 paranoid projection
 in paranoid psychosis, 80
- paranoid psychosis
 grandiose expansiveness, 80
 hostile belligerence, 80
 paranoid projection, 80
- paraphilias, 573
- Parkinson's disease, 95, 167, 351
 use of MAO-B inhibitors, 327–329
- Parkinsonian dementia
 cognitive symptoms, 85

Index

- parkinsonism
 drug-induced, 133–136
- paroxetine
 discontinuation reactions, 298–299
 side effects, 298–299
 unique properties, 298–299
- partial agonist action
 G-protein-linked receptors, 37–42
 ligand-gated ion channels, 58–61
- perceptual distortions in psychosis, 80
- performance-enhancing drug
 GHB, 468
- perimenopausal women
 and bipolar disorder, 385
 effectiveness of SSRIs and SNRIs,
 307–308
 treatment of depression, 307–308
 vasomotor symptoms, 305, 307–308
- Periodic Limb Movement Disorder
 (PLMD), 462
- perospirone
 pharmacologic properties, 213
- perphenazine, 131
- Pertofran, 342
- phantom limb pain, 425
- pharmaceutical industry, 286
- pharmacodynamic actions of drugs, 47
- pharmacokinetics, 46–47
- phencyclidine (PCP), 67, 107–108, 563
- phenelzine, 327
- phentermine, 573
- phentermine/topiramate ER (Qsmia),
 566–569
- phenylalkylamines, 562
- phosphatases, 11, 13–17
- phosphodiesterase 4 (PDE4)
 inhibitors, 500
- phosphoprotein cascade triggering
 gene expression, 16–18
- phosphoprotein messengers, 13–16
- Pick's dementia
 cognitive symptoms, 85
- pimozide, 49, 131
- “pines” (peens), 154, 162
 pharmacologic properties, 190
- piperidinedione derivatives, 559
- Piportil, 131
- pipothiazine, 131
- placebo effect
 in antidepressant clinical trials, 285
- plasma membrane neurotransmitter
 transporters, 29–30
- positive allosteric modulators (PAMs),
 65–67
 AMPA PAMs (AMPAkines), 228
 benzodiazepines, 403
- postmenopausal women
 effectiveness of SSRIs and
 SNRIs, 308
- postpartum depression, 245, 361
- postpartum period
 bipolar disorder risk, 385
- postpartum psychosis, 361
- post-stroke dementia
 cognitive symptoms, 85
- postsynaptic elements, 1
- postsynaptic neuron, 6
- posttraumatic stress disorder (PTSD),
 171, 268, 394, 405, 409
 blocking reconsolidation of fear
 memories, 414–415
 painful physical symptoms, 428
 treatments, 417–419
- pramipexole, 167, 385
- pravastatin, 49
- prazosin, 407
- PRC200-SS (triple reuptake inhibitor),
 365
- prefrontal cortex
 and ADHD, 471–479
 volume neurotransmission of
 dopamine, 8
- pregabalin, 71, 384–385, 403–405, 414,
 437
 properties, 379
- pregnancy
 and bipolar disorder, 385–386
 environmental factors in ADHD,
 480
 treatment of depression,
 357–361
 use of mood stabilizers, 385–386
- premenstrual dysphoric disorder, 290
- presynaptic elements, 1
- presynaptic neuron, 6
- pro-apoptotic actions, 46
- prolactin
 effects of atypical antipsychotics,
 150–151
 effects of elevated levels, 95
- Prolixin, 131
- pro-opiomelanocortin (POMC)
 neurons, 565
- protease inhibitors (for HIV/AIDS),
 49
- protein kinase A, 16
- Prothiaden, 342
- proton pump mechanism
 vesicular neurotransmitter
 transport, 34
- protriptyline, 342–343
- Prozac (fluoxetine), 6
- PRX03140 (5HT6 antagonist), 500
- PRX07034 (5HT6 antagonist), 500
- pseudobulbar affect, 366
- pseudocholinesterase, 522–525
- psilocybin, 562
- psychedelic hallucinations, 561
- psychiatric “vital signs”
- pain, 422, 441
 sleep, 444
- psychiatric disorders
 consequences of epigenetic
 influences, 26
 impulsive–compulsive aggression
 and violence, 574
- psychiatric insomnia
 and GABA_A PAMs, 455–459
- psychomimetic hallucinations, 561
- psychomotor retardation
 in depressive psychosis, 80
- psychopathology
 dimensions of, x–xi
- psychopathy, 574
- psychopharmacology
 influencing abnormal
 neurotransmission, 6
 targets within signal transduction
 cascades, 11
- psychosis
 clinical description, 79
 depressive psychosis, 80
 difficulty of definition, 79
 disorders associated with, 79
 disorders defined by, 79
 disorganized/excited psychosis, 80
 motor disturbances, 80
 nature of behavioral disturbances,
 79–80
 paranoid psychosis, 80
 perceptual distortions, 80
 types of, 79
- psychotherapy
 as an epigenetic “drug”, 352–353
 combined with antidepressants,
 352–353
 role in schizophrenia treatment,
 226–227
- psychotic depression, 245
 affective symptoms, 85
 positive symptoms, 85
- psychotic disorder due to a medical
 condition, 79
- psychotic disorders
 relationship to mood disorders,
 243–247
- psychotropic drug metabolism
 role of CYP450 (cytochrome P450)
 enzymes, 46–47
- psychotropic drug targets
 cytochrome P450 enzymes, 46–51
 enzymes, 43–51
 G-protein-linked receptors,
 35–43
 ligand-gated ion channels, 54
 monoamine transporters (SLC6
 family), 29–32

- neurotransmitter transporters, 28–34
 range of targets, 28
 sites of action, 28
 vesicular transporters (SLC18 gene family), 34
 pyromania, 573
- Qsmia (phentermine/topiramate ER), 566–569
- quetiapine, 49–50, 156, 159, 162, 171, 173–174, 176, 300, 313, 381, 383, 460
 effects at different doses, 185–189
 effects in different formulations, 185
 in combinations of mood stabilizers, 385
 metabolic risk, 173
 pharmacologic properties, 183–189
 quinidine, 366
- racemic citalopram, 299
 radafaxine, 310
 Raf (kinase), 17
 ramelteon, 453, 457
 rapacuronium, 335
 rapid cycling in mood disorders, 238
 antidepressant induced, 382
- Ras protein, 17
 rasagiline, 327
 reboxetine, 312
 recurrent thoughts, 395
 Research Domain Criteria
 in DSM, x
 use for diagnosis, 474
- reserpine, 34
 restless legs syndrome (RLS), 462
 retrograde (reverse)
 neurotransmission, 6
- reverse transcriptase inhibitors (for HIV/AIDS), 49
 reversible inhibitors of MAO-A (RIMAs), 333–335
- reward pathway
 mesolimbic dopamine circuit, 94–95, 542–543
- RG1678 (bitopertin), 232, 234
 RG3487 (acetylcholine booster), 500
- rifampin, 49
 riluzole, 384
 properties, 379–380
- rimonabant, 556, 561
 risperidone, 48, 162, 171, 173, 385
 metabolic risk, 173
 pharmacologic properties, 190–194
See also paliperidone.
- rivastigmine, 526–527
- RNA polymerase, 18–20
 RNA translation, 20
- ropinirole, 167, 385
 RSG4 gene, 116
 RSK (ribosomal S6 kinase), 18
- SAM-315 (5HT₆ antagonist), 500
 SAM-531 (5HT₆ antagonist), 500
 SAMe (S-adenosyl-methionine), 24, 350
- sarcosine (GlyT1 inhibitor), 232, 234
 SB334867 (SORA-1 agent), 464
 SB408124 (SORA-1 agent), 464
 SB410220 (SORA-1 agent), 464
 SB649868 (almorexant), 463
 SB674042 (SORA-1 agent), 464
 SB742457 (5HT₆ antagonist), 500
 SCH 1381252 (beta secretase inhibitor), 522
- schizoaffective disorder, 243–247
 affective symptoms, 85
 and psychosis, 79
 positive symptoms, 85
- schizobipolar disorder, 243–247
 schizoid personality disorder, 245
 schizophrenia, 85
 amygdala neuroimaging, 122–126
 and psychosis, 79
 brain circuits and symptom dimensions, 85–86
 cardiovascular disease risk, 80–81
 definition, 81
 direct and indirect costs
 in the US, 81
 dopamine hypothesis of, 86, 89–96
 dorsolateral prefrontal cortex (DLPFC) neuroimaging, 122–126
 dysconnectivity genes, 115–116
 dysconnectivity of neurons, 114–120
 environmental factors, 114–120
 genetic risk factors, 114–120
 hippocampal dysfunction, 123
 incidence, 80
 influence of epigenetics, 114–115
 life expectancy of patients, 80–81
 linking NMDA receptor hypofunction and dopamine hypotheses, 111–114
 mortality rate, 80–81
 neurodevelopmental factors, 114–120
 neuroimaging circuits, 120–126
 neuroimaging epistasis, 126–128
 neuroimaging of gene effects, 126–128
 neurotransmitters and pathways involved, 86–114
- NMDA receptor hypofunction
 hypothesis of, 107–111
 relationship to mood disorders, 243–247
 risk genes, 115–116
 suicide risk, 80–81
 susceptibility genes, 114–120
 treatment-resistant affective symptoms, 85
 ventromedial prefrontal cortex (VMPFC) neuroimaging, 122–126
- schizophrenia and dopamine, 86–96
 dopaminergic neurons, 86–89
 key dopamine pathways in the brain, 91
 mesocortical dopamine pathway and affective symptoms, 92–94
 mesocortical dopamine pathway and cognitive symptoms, 92–94
 mesocortical dopamine pathway and negative symptoms, 92–94
 mesolimbic dopamine pathway and negative symptoms, 94–95
 mesolimbic dopamine pathway and positive symptoms, 89–92
 mesolimbic dopamine pathway and reward, 94–95
 nigrostriatal dopamine pathway, 95
 thalamic dopamine pathway, 96
 tuberoinfundibular dopamine pathway, 95
- schizophrenia and glutamate, 96–111
 faulty NMDA synapses on GABA interneurons in prefrontal cortex, 107–111
 glutamate receptors, 101–102
 glutamate synthesis, 96
 key glutamate pathways in the brain, 102–106
 synthesis of D-serine, 96–101
 synthesis of glutamate co-transmitters, 96–101
 synthesis of glycine, 96–101
- schizophrenia future treatments, 227–235
 AMPAkinetics, 228
 glycine agonists, 228
 GlyT1 inhibitors, 232–234
 mGluR presynaptic antagonists/postsynaptic agonists, 228
 presymptomatic treatments, 235
 prodromal treatments, 235
 selective glycine reuptake inhibitors (SGRIs), 232–234
 targeting cognitive symptoms, 235
- schizophrenia symptoms
 affective blunting or flattening, 82
 affective symptoms, 83–84

Index

- schizophrenia symptoms (cont.)
 aggressive symptoms, 84
 alogia, 82
 anhedonia, 82
 asociality, 82
 assessment of negative symptoms, 82
 auditory hallucinations, 81
 avolition, 82
 cognitive symptoms, 83–85
 delusions, 81
 hallucinations, 81
 in other disorders, 85
 negative symptoms, 81–83, 113–114
 positive symptoms, 81, 111–113
 prodromal negative symptoms, 83
 subcategories by symptom dimensions, 83–85
 treatment, 83
- schizophrenia treatment
 early discoveries of antipsychotic drugs, 131
 psychotherapy and atypical antipsychotics, 226–227
See also antipsychotics; atypical antipsychotics; conventional antipsychotics.
- schizophreniform disorder, 245
 and psychosis, 79
- schizotypal personality disorder, 245
- scopolamine, 350, 523
- seasonal affective disorder, 245
- second-generation antipsychotics.
See atypical antipsychotics.
- second-messenger formation, 11–13
- sedating actions
 atypical antipsychotics, 171–173
- sedative hypnotic actions
 atypical antipsychotics, 171–173
- sedative hypnotics
 addiction to, 559
- selective glycine reuptake inhibitors (SGRIs), 101, 232–234, 413
- selective melatonin agonists, 457
- selective norepinephrine reuptake inhibitors (NRIs)
 atomoxetine, 312
 reboxetine, 312
- selegiline, 327, 333
- self-injurious behaviors, 85
- Selinco, 559
- semagacestat (LY450139), 521–522
- SEP-225289 (triple reuptake inhibitor), 365
- Serentil, 131
- serine hydroxymethyltransferase (SHMT), 101
- D-serine synthesis, 96–101
- D-serine transporter (D-SER-T), 101
- L-serine transporter (SER-T), 101
- serotonergic hypnotics, 457–458
- serotonin, 5, 237
 and anxiety, 405–406
 synthesis, 142
 termination of action, 142–143
See also 5HT (5-hydroxytryptamine).
- serotonin antagonist/reuptake inhibitors (SARIs), 322–326
- serotonin norepinephrine dopamine reuptake inhibitors (SNDRIs), 365
- serotonin norepinephrine reuptake inhibitors (SNRIs), 302–309, 405
 California rocket fuel (SNRI plus mirtazapine), 363
 desvenlafaxine, 307–308
 dopamine increase in the prefrontal cortex, 305–306
 duloxetine, 308–309
 effectiveness in postmenopausal women, 308
 effects of NET inhibition, 305–306
 in triple action combination (SSRI/SNRI/NDRI), 362–363
 milnacipran, 309
 venlafaxine, 306–307
- serotonin partial agonist reuptake inhibitors (SPARIs)
 vilazodone, 300–302
- serotonin selective reuptake inhibitors (SSRIs), 290–300, 405
 citalopram, 299
 common features, 291–296
 discontinuation reactions, 298–299
 effectiveness in postmenopausal women, 308
 escitalopram, 300
 fluoxetine, 297
 fluvoxamine, 299
 in triple action combination (SSRI/SNRI/NDRI), 362–363
 paroxetine, 298–299
 SERT blockade, 291–296
 sertraline, 297–298
 unique properties of individual SSRIs, 296–300
- serotonin toxicity/serotonin syndrome
 risk with MAOIs, 335–339
- serotonin transporter (SERT), 6, 142
 blockade by SSRIs, 291–296
 psychotropic drug target, 29–32
- serotonin vesicular transporter, 29
- SERT. *See* serotonin transporter.
- sertindole, 49–50
 pharmacologic properties, 215
- sertraline
 dopamine receptor (DAT) inhibition, 297–298
 sigma 1 receptor binding, 297–298
 unique properties, 297–298
- setipitilene, 318
- sexual acting out, 85
- sexual dysfunction, 95
- shared psychotic disorder, 245
- sibutramine, 573
- sigma 1 receptor binding
 fluvoxamine, 299
 sertraline, 297–298
- signal transduction cascades, 9–24
 activation of CREB transcription factor, 16–17
 forming a second messenger, 11–13
 G-protein-linked systems, 11
 hormone-linked systems, 11
 ion-channel-linked systems, 11
 kinases, 11, 13–18
 molecular mechanism of gene expression, 18–24
 neurotransmission trigger for gene expression, 18–24
 neurotransmitter first messengers, 10
 neurotrophin-linked systems, 11
 phosphatases, 11, 13–17
 phosphoprotein cascade triggering gene expression, 16–18
 phosphoprotein messengers, 13–16
 potential targets for psychotropic drugs, 11
 range of genes targeted by, 18
 sequence of messengers, 10–11
 targets, 13
 types of, 11
- silent antagonist drug action, 36–37
- simvastatin, 49
- Sinequan, 342
- single orexin receptor antagonists (SORAs), 463–464
- SLC1 gene family transporters, 29, 33
- SLC6 gene family transporters, 29, 33
 monoamine transporters, 32
- SLC17 gene family transporters, 29, 34
- SLC18 gene family transporters, 29, 34
 SLC18 gene family vesicular transporters
 psychotropic drug targets, 34
- SLC32 gene family transporters, 29, 34
- sleep
 as a psychiatric “vital sign”, 444
 effects of slow-wave sleep, 463
- sleep and wakefulness
 arousal spectrum, 445
 role of histamine, 450–453
 sleep/wake switch, 445–453

- sleep deprivation, 350
 problems associated with, 465
- sleepiness
 causes and consequences, 465
 mechanism of action of wake-promoting agents, 466–469
 problems associated with sleep deprivation, 465
 problems with cognitive performance, 465–466
- slow-wave sleep
 effects of, 463
- smoking
 effect on CYP450 1A2, 48
- social anxiety disorder, 405
 treatments, 416–417
- social phobia, 327
- sodium/chloride-coupled transporters, 29
- sodium oxybate
 wake-promoting agent, 468–470
- sodium potassium ATPase (adenosine triphosphatase), 31
- sodium pump, 30–31
- solanezumab, 521
- solute carrier gene families. *See SLC gene families.*
- somatization, 575
- SORA-1 agents, 464
- SORA-2 agents, 464
- SORAs (single orexin receptor antagonists), 463–464
- specific neutral amino acid transporter (SNAT), 96–98, 100
- SSR 241586 (GlyT1 inhibitor), 232
- SSR 504734 (GlyT1 inhibitor), 232
- SSRIs. *See* serotonin selective reuptake inhibitors.
- Stablon, 342
- STAR-D trial of antidepressants, 287
- statins
 drug interactions, 49
- Stelazine, 131
- stereotyped behaviors
 impulsive–compulsive dimension, 574
- stereotyped movement disorders
 impulsive–compulsive dimension, 574
- Sternbach criteria for serotonin toxicity, 335
- Stevens–Johnson Syndrome, 376
- stimulants, 468
 ADHD treatment, 487–493
 effects on appetite, 564
 use as drugs of abuse, 491–492
- stress, 365
 and depression vulnerability genes, 269–273
 and vulnerability to depression, 273
 BDNF effects, 268–269
 brain atrophy and depression, 268–269
 effects of environmental stress, 273
 effects on glucocorticoid levels, 268–269
 effects on the hippocampus, 268–269
 effects on the HPA (hypothalamic-pituitary-adrenal) axis, 268–269
 stress sensitization of brain circuits, 409
- substance abuse
 mood disorders related to, 251
- substance addictions, 543–563
 alcohol dependence, 551–559
 and the mesolimbic dopamine reward pathway, 542–543
 barbiturates, 559
 bath salts as synthetic stimulants, 563
 club drugs, 563
 development of compulsions, 541–542
 hallucinogens, 561–563
 inhalants, 563
 marijuana, 561
 nicotine, 547–553
 opiate addictions, 559–561
 sedative hypnotics, 559
 stimulant addiction process, 543–547
 toluene, 563
- substance-induced psychotic disorder
 and psychosis, 79
- substance use disorders, 385
- subsyndromal/ultra-high-risk psychosis prodrome, 245
- suicidality
 antidepressant induced, 382
 effects of lithium, 372
- suicide, 85
 in adolescents, 386
- sulpiride, 131, 168
 pharmacologic properties, 211
- supplementary motor area, 474
- suprachiasmatic nucleus (SCN), 313–317, 457
- Surmontil, 342
- suvorexant (MK-4305), 463–464
- SV2A transporter, 34
- symptom endophenotypes, x–xi
- SYN114 (5HT6 antagonist), 500
- SYN120 (5HT6 antagonist), 500
- synapses, 1
 asymmetric type, 1
 axoaxonic type, 1
 axodendritic type, 1
 axosomatic type, 1
- chemical neurotransmission
 process, 6
 direction of communication, 1
 dysconnectivity genes, 115–116
 experience-dependent development, 114–115
 location of, 1
 location of neurotransmitter, 1
 number in the human brain, 1–2
 postsynaptic elements, 1
 presynaptic elements, 1
 synaptic vesicle transporters, 29–32
- tapentadol, 340
- tardive dyskinesia, 95
- tasimelteon, 457
- tasofensine, 365, 571
- temper dysregulation, 386
- temperaments
 mood-related, 238
- Tennessee mood shine (mood-stabilizer combination), 385
- Tercian, 131
- terminal autoreceptors
 5HT1B/D receptors, 159–160
- tetrabenazine, 34
- tetrahydrobiopterin (BH4), 346
- thalamo-cortical glutamate pathway, 106
- THC (delta-9-tetrahydrocannabinol), 561
- theophyllin, 48
- therapeutic window
 atypical antipsychotics, 152–154
- thioridazine, 131
- thioridazone, 49
- thiothixene, 131
- Thorazine, 131
- thyroid hormones, 385
 as antidepressant augmenting agents, 350
 possible mood-stabilizing effect, 382
- tiagabine, 33
- tianeptine, 342
- tic disorders, 95
 impulsive–compulsive dimension, 574
- Tofranil, 342
- toluene, 563
- topiramate, 384–385, 559, 564
 properties, 379
- Tourette's syndrome
 impulsive–compulsive dimension, 574
- toxic epidermal necrolysis, 376
- tramadol, 339–340
- transcranial magnetic stimulation (TMS), 350–351

Index

- transcription factors, 18–20
 leucine zipper type, 20–21
 tranylcypromine, 327
 trazodone, 322–326, 341, 453
 insomnia treatment, 457–458
 trial-based therapy, 353
 triazolam, 49
 trichotillomania (compulsive hair pulling), 575
 tricyclic antidepressants, 49, 159, 312, 342–346
 antihistamine properties, 460
 interactions with MAOIs, 339–340
 potential for death in overdose, 343–346
 side effects, 343–346
 trifluoperazine, 131
 Trilafon, 131
 trimipramine, 342
 triple reuptake inhibitors (TRIs), 365
 TriRima (CX157), 335
 Tryprizol, 342
 tryptophan, 142
 tryptophan hydroxylase, 142, 346
 tuberoinfundibular dopamine pathway, 95
 tuberomammillary nucleus, 452, 463
 “two pips and a rip”, 154, 162
 pharmacologic properties, 211
 type 2 diabetes
 Alzheimer’s disease risk factor, 515
 typical antipsychotics.
See conventional antipsychotics.
 tyramine in the diet
 interaction with MAOIs, 331–335
 tyrosine, 86, 257
 tyrosine hydroxylase, 86, 257, 346
 tyrosine pump (transporter), 86
- unipolar depression, 237–238
 distinguishing from bipolar depression, 250–252
- vabacaserin, 159
 Valium (diazepam), 5
- valproate, 341, 372–373, 384, 386
 for mild mania, 383
 in combinations of mood stabilizers, 383
 mood-stabilizing properties, 373–375
 possible mechanisms of action, 373–374
 possible side effects in women, 385
 side effects, 375
 valproate sodium. *See* valproate.
 valproic acid. *See* valproate.
 varenicline, 385, 500, 549–551
 vascular dementia, 504
 cognitive symptoms, 85
 vasomotor symptoms
 in perimenopausal women, 307–308
 vasopressin 1B antagonists, 365
 venlafaxine, 48, 304
 extended-release formulation, 307
 properties, 306–307
 venlafaxine XR, 307
 ventromedial prefrontal cortex (VMPFC), 122
 in schizophrenia, 122–126
 vesicular acetylcholine transporter (VACHT), 29, 34
 vesicular glutamate transporters (VGLUT), 29, 34, 115
 vesicular inhibitory amino acid transporters (VIAATs), 29, 34, 397
 vesicular monoamine transporter 2 (VMAT2), 30, 86, 142, 258
 vesicular monoamine transporters (VMATs), 29
 vesicular neurotransmitter transporters, 29–32
 proton pump mechanism, 34
 SLC18 gene family targets for psychotropic drugs, 34
 subtypes and functions, 33–34
 vilazodone, 159, 300–302, 365, 405
 violence
 impulsive–compulsive behavior in psychiatric disorders, 574
- Vivactil, 342
 vocational rehabilitation, 227
 voltage-gated ion channels, 52
 structure and function, 67–74
 voltage-sensitive calcium channels (VSCCs), 9, 71–73
 subtypes, 71–73
 voltage-sensitive sodium channels (VSSCs), 9, 68–71
 volume neurotransmission, 6–8
 vortioxetine, 159, 162, 365, 500
- wake-promoting agents
 amphetamine, 468
 armodafinil, 468
 caffeine, 469
 gamma hydroxybutyrate (GHB), 468–470
 methylphenidate, 468
 modafinil, 466–468
 sodium oxybate, 468–470
 stimulants, 468
 Xyrem, 468–470
 weight loss treatment, 463
 Wellbutrin, 298
- women
 bipolar disorder and mood stabilizers, 385–386
 possible side effects of valproate, 385
- Xanax (alprazolam), 5
 Xyrem, 468–470
- Z-drugs, 341, 453–455, 559
 zaleplon, 341, 453, 455
 ziprasidone, 49–50, 159, 162, 171, 342
 metabolic risk, 173
 pharmacologic properties, 196–197
 Zolof, 298
 zolpidem, 341, 453–455
 zonisamide, 384–385, 564, 571
 zopiclone, 453–455
 zotepine, 48–50, 171
 pharmacologic properties, 190
 zuclopenthixol, 131